keyword
MENU ▼
Read by QxMD icon Read
search

EBMT

keyword
https://www.readbyqxmd.com/read/29335632/long-term-outcome-analysis-of-reduced-intensity-allogeneic-stem-cell-transplantation-in-patients-with-mantle-cell-lymphoma-a-retrospective-study-from-the-ebmt-lymphoma-working-party
#1
Stephen P Robinson, Ariane Boumendil, Herve Finel, Karl S Peggs, Patrice Chevallier, Jorge Sierra, Jürgen Finke, Xavier Poiré, Natacha Maillard, Noël Milpied, Ibrahim Yakoub-Agha, Mickey Koh, Nicolaus Kröger, Arnon Nagler, Yener Koc, Sascha Dietrich, Silvia Montoto, Peter Dreger
Reduced-intensity allogeneic stem cell transplantation (RIST) is usually reserved for patients with mantle cell lymphoma who relapse after an autoSCT. However, the long-term efficacy of RIST and its curative potential have not been clearly demonstrated. We studied the long-term outcome of patients receiving a RIST for MCL as reported to the EBMT. A total of 324 patients, median age 57 years (range 31-70), underwent a RIST between 2000 and 2008; 43% of the patients had received >3 lines of prior therapy, including an autoSCT in 46%...
January 15, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29335625/the-european-society-for-blood-and-marrow-transplantation-ebmt-consensus-guidelines-for-the-detection-and-treatment-of-donor-specific-anti-hla-antibodies-dsa-in-haploidentical-hematopoietic-cell-transplantation
#2
REVIEW
Stefan O Ciurea, Kai Cao, Marcelo Fernadez-Vina, Piyanuch Kongtim, Monzr Al Malki, Ephraim Fuchs, Leo Luznik, Xiao-Jun Huang, Fabio Ciceri, Franco Locatelli, Franco Aversa, Luca Castagna, Andrea Bacigalupo, Massimo Martelli, Didier Blaise, Rupert Handgretinger, Denis-Claude Roy, Paul O'Donnell, Asad Bashey, Hillard M Lazarus, Karen Ballen, Bipin N Savani, Mohamad Mohty, Arnon Nagler
Haploidentical donors are now increasingly considered for transplantation in the absence of HLA-matched donors or when an urgent transplant is needed. Donor-specific anti-HLA antibodies (DSA) have been recently recognized as an important barrier against successful engraftment of donor cells, which can affect transplant survival. DSA appear more prevalent in this type of transplant due to higher likelihood of alloimmunization of multiparous females against offspring's HLA antigens, and the degree of mismatch...
January 15, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29330402/chronic-graft-versus-host-disease-features-in-double-unit-cord-blood-transplantation-according-to-national-institutes-of-health-2005-cgvhd-consensus-criteria
#3
Hiromi Hayashi, Annalisa Ruggeri, Fernanda Volt, Jan J Cornelissen, Gerard Socié, Henrik Sengeloev, Mauricette Michallet, Dimitrios Karakasis, Eefke Petersen, Jean Yves Cahn, Hendrik Veelken, Mélanie Mercier, Pierre-Simon Rohrlich, Hanadi Rafii, Chantal Kenzey, Erick Xavier, Rafael F Duarte, Grzegorz W Basak, Vanderson Rocha, Eliane Gluckman
No abstract text is available yet for this article.
January 12, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29330396/comparable-survival-using-a-cmv-matched-or-a-mismatched-donor-for-cmv-patients-undergoing-t-replete-haplo-hsct-with-pt-cy-for-acute-leukemia-a-study-of-behalf-of-the-infectious-diseases-and-acute-leukemia-working-parties-of-the-ebmt
#4
Simone Cesaro, Roberto Crocchiolo, Gloria Tridello, Nina Knelange, Maria Teresa Van Lint, Yener Koc, Fabio Ciceri, Zafer Gülbas, Johanna Tischer, Boris Afanasyev, Benedetto Bruno, Luca Castagna, Didier Blaise, Mohamad Mohty, Giuseppe Irrera, J L Diez-Martin, Luca Pierelli, Pietro Pioltelli, Mutlu Arat, Mario Delia, Franca Fagioli, Gerhard Ehninger, Mahmoud Aljurf, Angelo Michele Carella, Hakan Ozdogu, Malgorzata Mikulska, Per Ljungman, Arnon Nagler, Jan Styczynski
The role of donor CMV serostatus in the setting of non T-cell depleted haplo-HSCT with post-transplant cyclophosphamide (PT-Cy) has not been specifically addressed so far. Here we analyzed the impact of the donor CMV serological status on the outcome of 983 CMV seropositive (CMV+), acute leukemia patients receiving a first, non T-cell depleted haplo-HSCT registered in the EBMT database. The 1-year NRM was 21.3% (95% CI: 18.4-24.8) and 18.8% (95% CI: 13.8-25.5) in the CMV D+/R+ and D-/R+ pairs, respectively (p = 0...
January 12, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29330391/impact-of-antithymocyte-globulin-doses-in-reduced-intensity-conditioning-before-allogeneic-transplantation-from-matched-sibling-donor-for-patients-with-acute-myeloid-leukemia-a-report-from-the-acute-leukemia-working-party-of-european-group-of-bone-marrow-transplantation
#5
Raynier Devillier, Myriam Labopin, Patrice Chevallier, Marie-Pierre Ledoux, Gérard Socié, Anne Huynh, Jean-Henri Bourhis, Jean-Yves Cahn, Gabrielle Roth-Guepin, Ghulam Mufti, Déborah Desmier, Mauricette Michallet, Nathalie Fegueux, Fabio Ciceri, Fréderic Baron, Didier Blaise, Arnon Nagler, Mohamad Mohty
Antithymocyte globulin (ATG) is commonly used for graft-vs.-host disease (GVHD) prophylaxis in unrelated donor allogeneic transplantation (Allo-HSCT). However, its use is still controversial in matched sibling donor (MSD) Allo-HSCT, notably after reduced intensity conditioning (RIC). ATG dose may influence the outcome, explaining in part the discordant conclusions in MSD Allo-HSCT. We, therefore, analyzed the impact of ATG doses in patients with acute myeloid leukemia in first complete remission undergoing RIC Allo-HSCT from a MSD...
January 12, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29325112/autologous-haematopoietic-stem-cell-transplantation-ahsct-in-severe-crohn-s-disease-a-review-on-behalf-of-ecco-and-ebmt
#6
John A Snowden, Julián Panés, Tobias Alexander, Matthieu Allez, Sandro Ardizzone, Daan Dierickx, Jürgen Finke, Peter Hasselblatt, Chris Hawkey, Majid Kazmi, James O Lindsay, Francesco Onida, Azucena Salas, Riccardo Saccardi, Severine Vermeire, Montserrat Rovira, Elena Ricart
Despite the major recent progress in the treatment of Crohn's disease (CD), there is a subset of patients in whom the disease runs an aggressive course with progressive tissue damage requiring early and repeated surgical management. Increasing evidence supports sustained and profound improvement in gastrointestinal parameters and quality of life following high dose immunosuppressive therapy and autologous haematopoietic stem cell transplantation (AHSCT) compared to standard therapy in this context. In addition, international transplant registry data reflects the use of AHSCT in CD outside of trials in selected patients...
January 8, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29288817/low-body-mass-index-is-associated-with-increased-risk-of-acute-gvhd-after-umbilical-cord-blood-transplantation-in-children-and-young-adults-with-acute-leukemia-a-study-on-behalf-of-eurocord-and-the-ebmt-pediatric-disease-working-party
#7
Annalisa Paviglianiti, Jean Hugues Dalle, Mouhab Ayas, Jan Jaap Boelens, Fernanda Volt, Anna Paola Iori, Mair Pedro de Souza, Miguel Angel Diaz, Gerard Michel, Franco Locatelli, Charlotte Jubert, Ibrahim Yakoub-Agha, Henrique Bittencourt, Yves Bertrand, Chantal Kenzey, Karina Tozatto Maio, Hiromi Hayashi, Vanderson Rocha, Peter Bader, Eliane Gluckman, Annalisa Ruggeri
Body mass index (BMI) might influence outcomes after allogeneic stem cell transplantation (HSCT). However, the impact of BMI on survival in children undergoing HSCT is not well defined, with conflicting results being reported on this issue. We analyzed 855 patients aged 2 to 20 years with diagnosis of acute leukemia who underwent umbilical cord blood transplantation (UCBT) from 1990 to 2015. Patients were classified according to BMI as normal (5th-85th percentile), underweight (<5th percentile), overweight (85th-95th percentile) and obese (>95th percentile) using growth charts for age and gender...
December 27, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29247780/intravenous-busulfan-compared-with-treosulfan-based-conditioning-for-allogeneic-stem-cell-transplantation-in-acute-myeloid-leukemia-a-study-on-behalf-of-the-acute-leukemia-working-party-of-ebmt
#8
Avichai Shimoni, Myriam Labopin, Bipin Savani, Rose-Marie Hamladji, Dietrich Beelen, Ghulam Mufti, Gerard Socié, Jeremy Delage, Didier Blaise, Patrice Chevallier, Edouard Forcade, Eric Deconinck, Mohamad Mohty, Arnon Nagler
Dose-intensity of the conditioning regimen has significant impact on the outcomes after stem-cell transplantation (SCT) for AML. Most studies have shown more relapse, less non-relapse mortality (NRM) and similar overall-survival after reduced-intensity and myeloablative conditioning. There is limited data on the dose-equivalence and expected outcomes of treosulfan-based compared with busulfan-based conditioning. We compared SCT outcomes after fludarabine with either intravenous-busulfan (ivBu) at myeloablative dose (FB4, ivBu 12...
December 13, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29242299/allogeneic-stem-cell-transplantation-benefits-for-patients-%C3%A2-60-years-with-acute-myeloid-leukemia-and-flt3-itd-a-study-from-the-acute-leukemia-working-party-alwp-of-the-european-society-of-blood-and-marrow-transplantation-ebmt
#9
Xavier Poiré, Myriam Labopin, Emmanuelle Polge, Jakob Passweg, Charles Craddock, Didier Blaise, Jan J Cornelissen, Liisa Volin, Nigel H Russell, Gérard Socié, Mauricette Michallet, Nathalie Fegueux, Patrice Chevallier, Arne Brecht, Mathilde Hunault-Berger, Mohamad Mohty, Jordi Esteve, Arnon Nagler
Intermediate-risk cytogenetic acute myeloid leukemia with an internal tandem duplication of FLT3 (FLT3-ITD) is associated with a high risk of relapse and is now a standard indication for allogeneic stem cell transplantation. Nevertheless, most studies supporting this strategy have been performed in young patients. To address the benefit of allogeneic transplantation in elderly patients, we selected from the EBMT registry de novo intermediate-risk cytogenetic acute myeloid leukemia harboring FLT3-ITD in patients with an age equal or over the age of 60 years and transplanted from a related or unrelated donor between January 2000 and December 2015...
December 14, 2017: Haematologica
https://www.readbyqxmd.com/read/29241729/long-term-follow-up-of-ipex-syndrome-patients-after-different-therapeutic-strategies-an-international-multicenter-retrospective-study
#10
Federica Barzaghi, Laura Cristina Amaya Hernandez, Benedicte Neven, Silvia Ricci, Zeynep Yesim Kucuk, Jack Bleesing, Zohreh Nademi, Mary Anne Slatter, Erlinda Rose Ulloa, Anna Shcherbina, Anna Roppelt, Austen Worth, Juliana Silva, Alessandro Aiuti, Luis Murguia-Favela, Carsten Speckmann, Magda Carneiro-Sampaio, Juliana Folloni Fernandes, Safa Baris, Ahmet Ozen, Elif Karakoc-Aydiner, Ayca Kiykim, Ansgar Schulz, Sandra Steinmann, Lucia Dora Notarangelo, Eleonora Gambineri, Paolo Lionetti, William Thomas Shearer, Lisa Forbes, Caridad Martinez, Despina Moshous, Stephane Blanche, Alain Fisher, Frank M Ruemmele, Come Tissandier, M Ouachee-Chardin, Frédéric Rieux-Laucat, Marina Cavazzana, Waseem Qasim, Barbarella Lucarelli, Michael H Albert, Ichiro Kobayashi, Laura Alonso, Cristina Diaz De Heredia, Hirokazu Kanegane, Anita Lawitschka, Jong Jin Seo, Marta Gonzalez-Vicent, Miguel Angel Diaz, Rakesh Kumar Goyal, Martin G Sauer, Akif Yesilipek, Minsoo Kim, Yesim Yilmaz-Demirdag, Monica Bhatia, Julie Khlevner, Erick J Richmond Padilla, Silvana Martino, Davide Montin, Olaf Neth, Agueda Molinos-Quintana, Justo Valverde-Fernandez, Arnon Broides, Vered Pinsk, Antje Ballauf, Filomeen Haerynck, Victoria Bordon, Catharina Dhooge, Maria Laura Garcia-Lloret, Robbert G Bredius, Krzysztof Kałwak, Elie Haddad, Markus Gerhard Seidel, Gregor Duckers, Sung-Yun Pai, Christopher C Dvorak, Stephan Ehl, Franco Locatelli, Frederick Goldman, Andrew Richard Gennery, Mort J Cowan, Maria Grazia Roncarolo, Rosa Bacchetta
BACKGROUND: Immunedysregulation Polyendocrinopathy Enteropathy X-linked (IPEX) syndrome is a monogenic autoimmune disease caused by FOXP3 mutations. Because it is a rare disease, the natural history and response to treatments, including allogeneic hematopoietic stem cell transplantation (HSCT) and immunosuppression (IS), have not been thoroughly examined. OBJECTIVE: To evaluate disease onset, progression and long-term outcome of the two main treatments in long-term IPEX survivors...
December 11, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29217776/melphalan-140mg-m2-or-200mg-m2-for-autologous-transplantation-in-myeloma-results-from-the-collaboration-to-collect-autologous-transplant-outcomes-in-lymphoma-and-myeloma-calm-study-a-report-by-the-ebmt-chronic-malignancies-working-party
#11
Holger W Auner, Simona Iacobelli, Giulia Sbianchi, Cora Knol-Bout, Didier Blaise, Nigel H Russell, Jane F Apperley, David Pohlreich, Paul Browne, Guido Kobbe, Cecilia Isaksson, Stig Lenhoff, Christoph Scheid, Cyrille Touzeau, Esa Jantunen, Achilles Anagnostopoulos, Ibrahim Yakoub-Agha, Alina Tanase, Nicolaas Schaap, Wieslaw Wiktor-Jedrzejczak, Marta Krejci, Stefan O Schönland, Curly Morris, Laurent Garderet, Nicolaus Kröger
Melphalan at a dose of 200mg/m2 is standard conditioning prior to autologous haematopoietic stem cell transplantation for multiple myeloma, but a dose of 140mg/m2 is often used in clinical practice in patients perceived to be at risk of excess toxicity. To determine if melphalan 200 and melphalan 140 are equally effective and tolerable in clinically relevant patient subgroups we analysed 1964 first single autologous transplantation episodes using a series of Cox proportional-hazards models. Overall survival, progression-free survival, cumulative incidence of relapse, non-relapse mortality, haematopoietic recovery and second primary malignancy rates were not significantly different between the melphalan 140 (n=245) and melphalan 200 (n=1719) groups...
December 7, 2017: Haematologica
https://www.readbyqxmd.com/read/29128085/-hla-coding-in-promise-guidelines-from-the-francophone-society-of-bone-marrow-transplantation-and-cellular-therapy-sfgm-tc
#12
Nicole Raus, Catherine Faucher, Anne Kennel, Maguy Pereira, Cécile Veron, Ibrahim Yakoub-Agha, Pascale Loiseau
As part of the 7th Annual francophone workshop series on the harmonization of clinical practices in allogeneic stem cell transplantation held in Lille in September 2016, our workgroup discussed how transplant centers might follow a collective approach to coding data. This was done mainly by analyzing the study results found in the literature that do not provide clear answers. In addition, we discuss practical ways of coding for both donor and recipient HLA typing in the European bone marrow transplantation database called ProMISe which is managed by the European Society for Blood and Marrow Transplantation (EBMT)...
November 8, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/29094350/transplant-results-in-adults-with-fanconi-anaemia
#13
Marc Bierings, Carmem Bonfim, Regis Peffault De Latour, Mahmoud Aljurf, Parinda A Mehta, Cora Knol, Farid Boulad, Abdelghani Tbakhi, Albert Esquirol, Grant McQuaker, Gulsan A Sucak, Tarek B Othman, Constantijn J M Halkes, Ben Carpenter, Dietger Niederwieser, Marco Zecca, Nicolaus Kröger, Mauricette Michallet, Antonio M Risitano, Gerhard Ehninger, Raphael Porcher, Carlo Dufour
The outcomes of adult patients transplanted for Fanconi anaemia (FA) have not been well described. We retrospectively analysed 199 adult patients with FA transplanted between 1991 and 2014. Patients were a median of 16 years of age when diagnosed with FA, and underwent transplantation at a median age of 23 years. Time between diagnosis and transplant was shortest (median 2 years) in those patients who had a human leucocyte antigen identical sibling donor. Fifty four percent of patients had bone marrow (BM) failure at transplantation and 46% had clonal disease (34% myelodysplasia, 12% acute leukaemia)...
November 2, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28977716/occurrence-of-graft-versus-host-disease-increases-mortality-after-umbilical-cord-blood-transplantation-for-acute-myeloid-leukemia-a-report-from-eurocord-and-the-alwp-of-the-ebmt
#14
Frédéric Baron, Annalisa Ruggeri, Eric Beohou, Myriam Labopin, Mohamad Mohty, Jaime Sanz, Stephane Vigouroux, Sabine Furst, Alberto Bosi, Patrice Chevallier, Jan J Cornelissen, Mauricette Michallet, Jorge Sierra, Dimitrios Karakasis, Bipin N Savani, Eliane Gluckman, Arnon Nagler
BACKGROUND: The efficacy of umbilical cord blood transplantation (UCBT) as treatment for acute myeloid leukemia (AML) relies on immune-mediated graft-versus-leukemia effects. Previous studies have suggested a strong association between graft-versus-host disease (GVHD) occurrence and graft-versus-leukemia effects after allogeneic hematopoietic cell transplantation. METHODS: Here, we evaluated the kinetics of relapse rate in correlation to GVHD occurrence after UCBT...
October 4, 2017: Journal of Internal Medicine
https://www.readbyqxmd.com/read/28971902/mixed-phenotype-acute-leukemia-outcomes-with-allogeneic-stem-cell-transplantation-a-retrospective-study-from-the-acute-leukemia-working-party-of-the-ebmt
#15
Reinhold Munker, Myriam Labopin, Jordi Esteve, Christoph Schmid, Mohamad Mohty, Arnon Nagler
Mixed phenotype acute leukemias are infrequent and considered high-risk. The optimal treatment approach and the role of allogeneic hematopoietic stem cell transplantation are not entirely clear. In this study, we investigated 519 patients with mixed phenotype acute leukemia in first complete remission who underwent allogeneic hematopoietic stem cell transplantation between 2000 and 2014 and were reported to the Acute Leukemia Working Party of the EBMT. The median age was 38.1 years (range 18- 75), by cytogenetics, 49...
September 29, 2017: Haematologica
https://www.readbyqxmd.com/read/28971504/relatively-favorable-outcome-after-allogeneic-stem-cell-transplantation-for-bcr-abl1-positive-aml-a-survey-from-the-acute-leukemia-working-party-of-the-european-society-for-blood-and-marrow-transplantation-ebmt
#16
Vladimir Lj Lazarevic, Myriam Labopin, Wu Depei, Ibrahim Yakoub-Agha, Anne Huynh, Per Ljungman, Nicolaas Schaap, Jan J Cornelissen, Natacha Maillard, Pietro Pioltelli, Tobias Gedde-Dahl, Stig Lenhoff, Mohamed Houhou, Jordi Esteve, Mohamad Mohty, Arnon Nagler
The aim of the study was to assess the role of allogeneic stem cell transplantation (SCT) in patients diagnosed with BCR-ABL1-positive acute myeloid leukemia (AML). Fifty-seven patients (median age, 48 years, range: 19-67) with BCR-ABL1 positive AML undergoing SCT were identified. The majority of the patients (70%) received a TKI before the transplant. At SCT 48 patients were in CR (45 in CR1), while 9 patients were transplanted in a more advanced stage of the disease. MRD was negative (BCR-ABL1/ABL < 10(4) ) at time of SCT in 36...
October 3, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28971503/high-dose-chemotherapy-and-autologous-stem-cell-transplantation-in-nodular-lymphocyte-predominant-hodgkin-lymphoma-a-retrospective-study-by-the-european-society-for-blood-and-marrow-transplantation-lymphoma-working-party
#17
Saad Akhtar, Silvia Montoto, Ariane Boumendil, Herve Finel, Tamas Masszi, Pavel Jindra, Damir Nemet, Stephan Fuhrmann, Yves Beguin, Luca Castagna, Felicetto Ferrara, Saveria Capria, Ram Malladi, Jose Maria Moraleda, Adrian Bloor, Hervé Ghesquières, Julia Meissner, Anna Sureda, Peter Dreger
Whilst autologous stem cell transplantation (auto-SCT) is considered standard of care for relapsed/refractory classical Hodgkin lymphoma, the role of auto-SCT in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is not well defined due to limited data. We report the first study on auto-SCT for NLPHL with a larger cohort. Eligible for this retrospective registry study were patients reported to the EBMT between 2003 and 2013, aged 18 or older with relapsed/refractory NLPHL who underwent first auto-SCT with disease chemosensitive to salvage therapy...
January 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/28939455/neurocognitive-dysfunction-in-hematopoietic-cell-transplant-recipients-expert-review-from-the-late-effects-and-quality-of-life-working-committee-of-the-center-for-international-blood-and-marrow-transplant-research-and-complications-and-quality-of-life-working
#18
REVIEW
Debra Lynch Kelly, David Buchbinder, Rafael F Duarte, Jeffrey J Auletta, Neel Bhatt, Michael Byrne, Melissa Gabriel, Anuj Mahindra, Maxim Norkin, Helene Schoemans, Ami J Shah, Ibrahim Ahmed, Yoshiko Atsuta, Grzegorz W Basak, Sara Beattie, Sita Bhella, Christopher Bredeson, Nancy Bunin, Jignesh Dalal, Andrew Daly, James Gajewski, Robert Peter Gale, John Galvin, Mehdi Hamadani, Robert J Hayashi, Kehinde Adekola, Jason Law, Catherine J Lee, Jane Liesveld, Adriana K Malone, Arnon Nagler, Seema Naik, Taiga Nishihori, Susan K Parsons, Angela Scherwath, Hannah-Lise Schofield, Robert Soiffer, Jeff Szer, Ida Twist, Anne Warwick, Baldeep M Wirk, Jean Yi, Minoo Battiwalla, Mary E Flowers, Bipin Savani, Bronwen E Shaw
Hematopoietic cell transplantation (HCT) is a potentially curative treatment for children and adults with malignant and nonmalignant diseases. Despite increasing survival rates, long-term morbidity after HCT is substantial. Neurocognitive dysfunction is a serious cause of morbidity, yet little is known about neurocognitive dysfunction after HCT. To address this gap, collaborative efforts of the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation undertook an expert review of neurocognitive dysfunction after HCT...
September 20, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28892084/validation-of-the-revised-ipss-at-transplant-in-patients-with-myelodysplastic-syndrome-transformed-acute-myelogenous-leukemia-receiving-allogeneic-stem-cell-transplantation-a-retrospective-analysis-of-the-ebmt-chronic-malignancies-working-party
#19
C Scheid, L de Wreede, A van Biezen, C Koenecke, G Göhring, L Volin, J Maertens, J Finke, J Passweg, D Beelen, J J Cornelissen, M Itälä-Remes, P Chevallier, N Russell, E Petersen, N Milpied, C Richard Espiga, A Peniket, J Sierra, G Mufti, C Crawley, J H Veelken, P Ljungman, J Y Cahn, E P Alessandrino, T de Witte, M Robin, N Kröger
The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate the use of the IPSS-R assessed before transplant rather than at diagnosis we performed a retrospective analysis of the EBMT database. A total of 579 patients had sufficient information available to calculate IPSS-R at transplant. Median overall survival (OS) from transplant was significantly different according to IPSS-R: very low 23.6 months, low 55...
November 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28807768/european-group-for-blood-and-marrow-transplantation-risk-score-predicts-the-outcome-of-patients-with-acute-leukemia-receiving-single-umbilical-cord-blood-transplantation
#20
Xiaoyu Zhu, Lulu Huang, Changcheng Zheng, Baolin Tang, Huilan Liu, Liangquan Geng, Juan Tong, Lei Zhang, Xuhan Zhang, Wen Yao, Kaidi Song, Xingbing Wang, Kaiyang Ding, Zimin Sun
The European Group for Blood and Marrow Transplantation (EBMT) risk score has been implemented as an important tool to predict patient outcomes after allogeneic hematopoietic stem cell transplantation. However, to our knowledge, this score has never been applied in cases of single umbilical cord blood transplantation (sUCBT). We retrospectively analyzed 207 consecutive patients with acute leukemia who received sUCBT at our center between February 2011 and December 2015. The probabilities of 3-year overall survival (OS) and leukemia-free survival (LFS) of the entire cohort were 65...
August 12, 2017: Biology of Blood and Marrow Transplantation
keyword
keyword
115198
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"